Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 1.00 |
| ▸ | DPP4 | P27487 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 11/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987786 | 0.83 | ANPEP (0.70) | ANPEPDPP4CRHBPCRHR2LMNA | |
| SCHEMBL987346 | 0.81 | DPP4 (0.68) | ANPEPDPP4CRHBPCRHR2LMNA | |
| SCHEMBL29382376 | 0.81 | DPP4 (0.68) | ANPEPDPP4CRHBPCRHR2LMNA | |
| SCHEMBL9812607 | 0.81 | ANPEP (0.68) | ANPEPDPP4ESR1CRHBPCRHR2 | |
| SCHEMBL22221562 | 0.80 | ANPEP (0.66) | ANPEPDPP4CRHBPCRHR2LMNA | |
| SCHEMBL16601770 | 0.77 | NPC1 (0.66) | ANPEPDPP4ESR1CRHBPCRHR2 | |
| SCHEMBL173289 | 0.77 | ANPEP (1.00) | ANPEPDPP4ESR1ESR2 | |
| SCHEMBL9812679 | 0.77 | ANPEP (0.62) | ANPEPDPP4LMNAMAPTHTT | |
| SCHEMBL9588813 | 0.76 | ANPEP (0.79) | ANPEPDPP4ESR1ESR2 | |
| SCHEMBL31012107 | 0.75 | ESR1 (0.90) | ANPEPDPP4ESR1ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2769715-A2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8410053-B2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120232004-A1 | Methods for Treating Autoimmune Disorders, and Reagents Related Thereto | THE BRIGHAM AND WOMEN'S HOSPITAL (US) | 2012-09-13 | — | — | US | disclosed |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | BRIGHAM AND WOMEN"S HOSPITAL (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1487471-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS AND REAGENTS RELATED THERETO | Trustees of Tufts College (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003045228-A9 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TUFTS COLLEGE (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003045228-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | DNPEP, PREP, VIP | ANPEP 21/4885DPP4 11/4885ESR1 4571/4885 |
| US-20120232004-A1 | Methods for Treating Autoimmune Disorders, and Reagents Related Thereto | TNF, HLA-DRB1, IAPP | ANPEP 2453/4885DPP4 307/4885ESR1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.